Meril, a leader in cardiovascular and structural heart solutions, known for its next-generation transcatheter heart valve technologies, has announced the launch of its next-generation Myval Octapro THV.

Meril says its Myval Octapro THV underscores dedication to redefining TAVR technology and shaping the future of structural heart care.

The company claims the Myval THV series has a ‘profound impact’ & has been ‘instrumental’ in advancing transcatheter aortic valve replacement (TAVR) therapy.

Characterised by reduced frame foreshortening leading to higher operator control and predictive deployment; availability of a large size matrix comprising of conventional, intermediate and extra-large valve diameters allowing better bioprosthetic valve sizing for individual patient and supported by a large pool of clinical evidence substantiates the day-to-day clinical utility of the device globally.

The clinical efficacy of the Myval THV series was demonstrated through the LANDMARK RCT published in THE Lancet(Baumbach et. al. Volume 403, Issue 10445, P2695-2708, June 22, 2024), conducted by renowned clinicians worldwide including 768 real world patients in 16 countries across 31 centers.